Press release summary
Nabsys announced a preprint describing a method that combines CRISPR/Cas9 with electronic genome mapping, or EGM. The company said the approach uses ultra-long DNA molecules to evaluate CRISPR binding and guide RNA performance while also changing where its mapping platform generates structural information.
Researchers used CRISPR-mediated labeling changes to support both genome-wide analysis and targeted examination of selected regions. The work included detection of repeat expansions in the FXN gene associated with Friedreich ataxia. Nabsys said the method could also be explored for other difficult repeat-expansion regions and for assessing potential off-target CRISPR activity. The work was performed with the company’s OhmX research-use-only platform, which combines electronic detection, nanofluidics and computational analysis.
Why it matters for laboratories
The method could give genomics laboratories another way to investigate large structural variants and repetitive regions that can be difficult to resolve with conventional sequencing or cytogenetic techniques. It may also connect genome-mapping workflows with guide RNA optimization for cell and gene therapy research. The findings are preliminary, however. The cited paper is a preprint that has not undergone peer review, and the release does not establish clinical validity or routine diagnostic performance.
Original source: Nabsys release distributed through PR Newswire, Sept. 21, 2026.
